Atara Biotherapeutics (NASDAQ:ATRA) Issues Earnings Results

Atara Biotherapeutics (NASDAQ:ATRA) posted its earnings results on Friday. The biotechnology company reported ($1.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.82) by $2.63, Zacks reports.

Atara Biotherapeutics Trading Up 1.5 %

Shares of NASDAQ ATRA traded up $0.10 during midday trading on Friday, reaching $6.90. The company had a trading volume of 33,230 shares, compared to its average volume of 255,670. Atara Biotherapeutics has a 1 year low of $5.40 and a 1 year high of $20.81. The business’s 50-day simple moving average is $9.85 and its 200 day simple moving average is $9.71. The stock has a market cap of $39.74 million, a P/E ratio of -0.27 and a beta of 0.46.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Canaccord Genuity Group dropped their price objective on Atara Biotherapeutics from $21.00 to $17.00 and set a “buy” rating on the stock in a research report on Friday, January 17th. Rodman & Renshaw initiated coverage on shares of Atara Biotherapeutics in a report on Friday, December 20th. They issued a “buy” rating and a $25.00 price target on the stock. RODMAN&RENSHAW lowered shares of Atara Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 21st. HC Wainwright restated a “neutral” rating on shares of Atara Biotherapeutics in a research note on Tuesday, January 28th. Finally, TD Cowen raised Atara Biotherapeutics to a “strong-buy” rating in a research report on Friday, November 29th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $17.75.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.